AZD-4512

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameAZD-4512
Drug Alias NameAZD4512AZD-4512
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD22DNA topoisomerase I inhibitors
TargetsCD22DNA topoisomerase I
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[10
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A